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Abstract Here we show that human melanocytes express the 
corticotropin releasing factor (CRF) gene and produce CRF 
peptide. The CRF production and secretion is markedly 
stimulated by ultraviolet B (UVB) radiation. This is the first 
demonstration that cutaneous melanocytes respond to environ- 
mental stress (UVB) through the production of CRF. 
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1. Introduction 
A classical pathway for response to stress in vertebrates is 
via induction of corticotropin releasing factor (CRF) in the 
hypothalamus with subsequent production and processing of 
proopiomelanocortin (POMC) by the pituitary [ 1,2]. Recently, 
it was documented that skin, the largest body organ, is not 
only a target for POMC peptide regulation but also a site of 
POMC gene expression itself [3-lo]. 
Ultraviolet radiation is a major environmental stressor of 
the skin. Following damage by UVB radiation, both kerati- 
nocytes and melanocytes are activated through cascade reac- 
tions resulting in production and processing of POMC, up- 
regulation of MSH receptors, and increased melanin content 
[8,9,11,12]. Because CRF is the main regulator of POMC ex- 
pression we decided to investigate whether CRF is produced 
by skin cells and whether this production is stimulated by 
UVB. 
2. Materials and methods 
2.1. Cell culture 
Culture conditions of foreskin human melanocytes and UVB treat- 
ment protocols were detailed previously [8,9,11]. Briefly, during UVB 
treatment the culture medium was replaced with phosphate-buffered 
physiologic saline (PBS). Doses of 10 and 20 mJ/cm2 were used (en- 
ergy range of 260-380 nm with peak at 302 nm; UVM-57 LAMP, 
UVP Inc., CA). After treatment the PBS was replaced by regular 
media and cells were incubated at 37°C for 24 h. The media and cells 
were collected separately and used for RNA or peptide extractions. 
2.2. Reverse transcription-polymerase chain reaction and Southern blot 
hybridization 
Reverse transcription-polymerase chain reaction (RT-PCR) assays 
were performed as described previously [7]. Briefly, total RNA after 
extraction with the TRIzol kit (Gibco-BRL, Gaithersburg, MD) was 
reverse-transcribed using the Superscript preamplification system 
(Gibco-BRL). The fragment of 413 bp derived from the CRH exon 
2 transcript [13] was amplified using program and primers with se- 
quences described previously [7]. As a negative control RNA samples 
without prior reverse transcription were run in parallel. The GAPDH 
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control gene was amplified as described [7]. The PCR products after 
separation on 1.5% agarose were Southern blotted to nylon mem- 
branes (Oncor, Gaithersburg, MD) [7,14]. The amplified cDNA was 
hybridized with [a-32P]dCTP-labelled human CRF cDNA and after 
washing membranes were exposed on Kodak XAR film [7]. 
2.3. CRF immunoassays 
CRF peptides were extracted from melanocytes and conditioned 
media as described [8,9] using SEPCOL-1 containing 200 mg of Cl8 
and followed the manufacturer’s protocol (Cat. No. RIK-SEPCOLl, 
Peninsula, Belmont, CA). The eluted peptides after lyophilization 
were suspended in RIA buffer and CRF immunoreactivity was meas- 
ured using CRF RIA kit (Advanced ChemTech, Kentucky) or were 
suspended in 0.1% trifluoroacetic acid (TFA) and separated by re- 
verse-phase high pressure liquid chromatography (RP-HPLC) as fol- 
lows. The reconstituted samples in 0.1% TFA (100 ~1) were injected 
onto the RP-HPLC Beckman Ultrasphere Cl8 IP column (4.6 
mm X 15.0 cm, 5 Km pore size). Peptides were eluted with an increas- 
ing linear gradient of acetonitrile in 0.1% TFA (flow rate = 1 ml/min) 
using an ISCO Dual Pump Model 2350 HPLC system with an ISCO 
V4 variable wavelength UV detector. Starting at 11 min, 1 ml frac- 
tions were collected, lyophilized and assayed using CRF RIA kit. The 
corrected elution time of the CRF peptide was calibrated prior the 
sample separation with human CRF peptide synthesized commercially 
(Molecular Research Lab., North Carolina). 
3. Results and discussion 
Human melanocytes expressed CRF mRNA (Fig. 1). This 
expression was accompanied by production of CRF peptide 
GAPDH *m 
Fig. 1. RT-PCR Southern blot analysis of CRF mRNA expression 
in human melanocytes. Upper panel: PCR amplified RNA without 
reverse trascription (negative control); middle panel: RT-PCR am- 
plified CRF fragment; lower panel: RT-PCR amplified GAPDH 
(semiquantitative control). UVB doses (mJ/cm’): 0, control (lane 1); 
10 (lane 2); 20 (lane 3). 
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Table 1 
Production of CRF by human melanocytes exposed to UVB radiation 
Treatment CRF production (pg/O.5 mg cellular protein) 
Cells P-value Media P-value 
Control 31.3f 15.0 _ 23.0? 2.7 
UVB 10 mJ/cm2 93.7? 5.1 0.005 38.92 1.1 0.001 
UVB 20 mJ/cm2 270.0 + 10.1 0.000 49.3 f 9.3 0.021 
Data represent means rf. S.E. from 5 (cells) or 6 (media) assays combined from two independent experiments. P-values of the difference between 
control and UV treated cells were calculated using independent Student t-tests. 
8 20 25 30 3.5 40 45 50 
ELUTION TIME (minutes) 
Fig. 2. RP-HPLC identification of CRF immunoreactivity from 
UVB treated melanocytes. CRF: CRF peptide standard eluting at 
the same time (30-32 min) as the radioimmunoreactivity peak de- 
tected by specific anti-CRF RIA kit. 
(Fig. 2). UVB stimulated both production and secretion of 
CRF by human melanocytes in culture (Table 1). The stimu- 
lation occurred at doses of 10 and 20 mJ/cm’, which in our 
previous experiments were optimal in stimulation of POMC 
peptide production, MSH receptor expression and stimulation 
of melanin synthesis [8,9,11,12]. 
CRF is a central regulator of POMC expression throughout 
the vertebrates [1,2]. Mammalian skin and melanocytes can 
produce POMC peptides including aMSH and ACTH [3- 
101, a process enhanced by UV radiation [4,8-lo]. The skin 
also expresses CRF receptor 1 (CRF-Rl) gene [14] and pro- 
duction of CRF-Rl mRNA can be stimulated by UVB [7]. 
Previously, we speculated that an equivalent to the ‘hypotha- 
lamic-pituitary-adrenal axis’ may operate in mammalian skin 
as a main coordinator and executor of the cutaneous response 
to stress [15]. Here we show for the first time that human 
melanocytes produce CRF peptide and that this process is 
markedly stimulated by UVB. Therefore, we propose that 
part of the skin response to UVB involves CRF production 
that in turn could induce POMC expression followed by an 
activation of the melanogenic system. 
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